Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24028121 | 0.81 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5490131 | 0.81 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL30261850 | 0.80 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26288696 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13589901 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5497908 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Bromide SCHEMBL5075013 | 0.79 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1891858 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10138682 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL30984798 | 0.78 | CHRNB2 (0.66) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | CHRNB2 600/4885CHRNA4 601/4885CHRNB4 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.